Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α Follow-Up Results

摘要: We treated 261 patients with Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) in phase after failure of IFN-alpha the Bcr-Abl tyrosine kinase inhibitor imatinib mesylate (400 mg/day given p.o.) and analyzed hematological cytogenetic responses, long-term prognosis, factors associated achievement major response survival, comparative survival similar other regimens. Median patient age was 55 years; 34% were 60 years or older, median chronic-phase duration 33 months. Overall, 94% achieved a complete response, 71% had [major (Ph+ cells <35%) 62% 45%]. At follow-up 17 months, 241 (92%) still taking mesylate; estimated 18-month freedom from progression rates 93 96%. Multivariate analysis identified long phase, marrow basophilia, high percentage Ph+ before therapy, prior resistance to as being adverse factors. This model used generate good-, intermediate- poor-risk subgroups who 93, 53, 34%, respectively. Univariate terms leukocytosis, percentages peripheral blasts, presence clonal evolution Achieving at 3 6 months therapy prolonged survival. In subset analysis, among 161 Ph-positive CML been better than those for previously summary, is highly effective failure. pretreatment treatment-associated that higher improved